



Colon-Targeted Drug Delivery using Prodrug Approach

Guest Editor:

Prof. Dr. Yunjin Jung

Laboratory of Biomedical
Chemistry, College of Pharmacy,
Pusan National University, Busan
609-735, Republic of Korea

Deadline for manuscript
submissions:

closed (20 March 2019)

Message from the Guest Editor

Dear Colleagues,

Colon-targeted drug delivery (CTDD) implies transport of a drug to the large intestine with no significant loss in the upper gastrointestinal tract upon oral administration of the drug. This increases drug availability at the target site and decreases drug absorption into blood, thus improving therapeutic and toxicological properties. For this reason, CTDD is applied to drugs for the treatment of colonic diseases, such as inflammatory bowel disease (IBD) and constipation. A prodrug, an inactive derivative of a drug, is designed to circumvent pharmacokinetic issues and be subsequently activated to the drug through biochemical processes within the body. Adoption of prodrug concept to CTDD gives a birth to colon-targeted prodrug (CTP). To date, a number of hydrophilic or polymeric carrier-linked CTPs, activated by microbial enzymes in the large intestine, have been developed, largely aiming at IBD treatment. Any contributions to add knowledge and insights on CTP design and application are welcome in this Special Issue.

Prof. Yunjin Jung
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of
Pharmacy, Rutgers, The State
University of New Jersey, William
Levine Hall, Room 225C, 160
Frelinghuysen Road, Piscataway,
NJ 08854-8020, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
[X@MDPIpharma](https://twitter.com/MDPIpharma)